252 related articles for article (PubMed ID: 34211575)
1. Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases.
Lin M; Hu X; Chang S; Chang Y; Bian W; Hu R; Wang J; Zhu Q; Qiu J
Evid Based Complement Alternat Med; 2021; 2021():6678422. PubMed ID: 34211575
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Sang A; Zhuo S; Bochanis A; Manautou JE; Bahal R; Zhong XB; Rasmussen TP
BioDrugs; 2024 Jun; ():. PubMed ID: 38914784
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
Verma A
Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
[TBL] [Abstract][Full Text] [Related]
7. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
8. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapy in neurology.
Lee JJ; Yokota T
J Pers Med; 2013 Aug; 3(3):144-76. PubMed ID: 25562650
[TBL] [Abstract][Full Text] [Related]
11. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
12. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
13. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides: A primer.
Scoles DR; Minikel EV; Pulst SM
Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
[TBL] [Abstract][Full Text] [Related]
15. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
Ly CV; Miller TM
Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide therapeutics in neurodegenerative diseases.
Scoles DR; Pulst SM
RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application.
Le BT; Chen S; Veedu RN
ACS Omega; 2023 Dec; 8(51):48650-48661. PubMed ID: 38162739
[TBL] [Abstract][Full Text] [Related]
18. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
19. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
20. Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases.
Maruyama R; Yokota T
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32947786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]